What is the latest PPLPHARMA stock price?
The latest stored price for PPLPHARMA is Rs 213.67 as of 2026-08-21.
gimli
PPLPHARMA stock AI analysis
PPLPHARMA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
PIRAMAL PHARMA LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available PPLPHARMA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹213.67
1W return
+3.40%
1M return
+15.62%
3M return
+21.35%
6M return
+33.10%
1Y return
+11.26%
Market cap
₹28,305.81 cr
PE
-90.26
PB
3.47
ROE
-3.85%
ROCE
+1.51%
RSI
65.23
Turnover
₹97.70 cr
Why it can matter in screens
- Momentum: PPLPHARMA is above 50DMA, above 200DMA; RSI is 65.23.
- Returns: 1D -1.38%, 1W +3.40%, 1M +15.62%, 3M +21.35%, 1Y +11.26%.
- Trend levels: 52W high ₹220.36, 52W low ₹158.10, off high -3.04%.
- Liquidity: latest turnover is ₹97.70 cr; volume vs 20D is +0.62%.
- Valuation/profitability: PE -90.26, PB 3.47, ROE -3.85%, ROCE +1.51%.
- Growth: 3Y sales CAGR +8.04%, 3Y profit CAGR n/a.
Quick Answers
Is PPLPHARMA above its 50DMA and 200DMA?
PPLPHARMA is above 50DMA, above 200DMA. The latest 50DMA is 184.99 and the latest 200DMA is 171.43.
What are PPLPHARMA PE, ROE and ROCE?
PPLPHARMA has PE -90.26, ROE -3.85%, and ROCE +1.51% in Gimli's latest available snapshot.
How has PPLPHARMA performed recently?
PPLPHARMA has returned +15.62% over 1 month, +21.35% over 3 months, and +11.26% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 2,269.92 cr | 304.17 cr | -69.39 cr | -0.52 |
| 2026-03-31 | 2,751.77 cr | 344.37 cr | -8.82 cr | -0.07 |
| 2025-12-31 | 2,139.87 cr | 208.12 cr | -136.19 cr | -1.03 |
| 2025-09-30 | 2,109.00 cr | 224.29 cr | -99.22 cr | -0.75 |
| 2025-06-30 | 1,933.71 cr | 204.41 cr | -81.70 cr | -0.62 |
| 2025-03-31 | 2,754.07 cr | 619.24 cr | 153.50 cr | 1.16 |
| 2024-12-31 | 2,204.22 cr | 366.92 cr | 3.68 cr | 0.03 |
| 2024-09-30 | 2,241.75 cr | 419.98 cr | 22.59 cr | 0.17 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 8,869.08 cr | 995.98 cr | -325.94 cr | -2.46 |
| 2025-03-31 | 9,151.18 cr | 1,652.57 cr | 91.13 cr | 0.69 |
| 2024-03-31 | 8,106.41 cr | 1,366.81 cr | 17.82 cr | 0.14 |
| 2023-03-31 | 7,032.41 cr | 894.25 cr | -186.46 cr | -1.54 |
| 2022-03-31 | 3,565.21 cr | 1,259.94 cr | 367.54 cr | 3.12 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 17,965.04 cr | 1,199.88 cr | 5,674.59 cr | 8,162.62 cr |
| 2025-03-31 | 15,677.59 cr | 368.98 cr | 4,856.47 cr | 8,125.47 cr |
| 2024-03-31 | 15,311.81 cr | 356.82 cr | 4,710.16 cr | 7,911.37 cr |
| 2023-03-31 | 14,522.56 cr | 195.59 cr | 5,637.08 cr | 6,773.50 cr |
| 2022-03-31 | 12,797.04 cr | 228.10 cr | 4,127.92 cr | 6,696.60 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 1,652.59 cr | 762.57 cr | n/a |
| 2025-03-31 | 892.30 cr | 227.92 cr | n/a |
| 2024-03-31 | 1,004.54 cr | 292.50 cr | n/a |
| 2023-03-31 | 483.89 cr | -480.86 cr | n/a |
| 2022-03-31 | 766.42 cr | -123.09 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +34.80% | +12.52% | +14.57% | +13.18% | +37.63% | +0.00% |
| 2026-03-31 | +34.86% | +30.18% | +15.61% | +14.12% | +19.01% | +0.00% |
| 2025-12-31 | +34.86% | +29.66% | +15.69% | +14.03% | +19.35% | +0.00% |
| 2025-09-30 | +34.86% | +30.27% | +14.89% | +13.11% | +19.47% | +0.00% |
| 2025-06-30 | +34.86% | +30.86% | +14.26% | +12.32% | +19.45% | +0.00% |
| 2025-03-31 | +34.95% | +31.49% | +14.78% | +12.73% | +18.44% | +0.00% |
| 2024-12-31 | +34.95% | +31.68% | +14.10% | +11.66% | +18.87% | +0.00% |
| 2024-09-30 | +34.95% | +31.73% | +13.81% | +11.21% | +19.07% | +0.00% |
| 2024-06-30 | +34.95% | +31.42% | +12.95% | +10.12% | +20.21% | +0.00% |
| 2024-03-31 | +35.02% | +30.59% | +12.12% | +9.01% | +21.89% | +0.00% |
| 2023-12-31 | +35.02% | +32.51% | +9.68% | +6.28% | +22.41% | +0.00% |
| 2023-09-30 | +35.02% | +32.37% | +8.02% | +3.80% | +24.21% | +0.00% |
| 2023-09-27 | +35.02% | +32.62% | +7.87% | +3.65% | +24.11% | +0.00% |
| 2023-08-22 | +35.02% | +32.23% | +7.83% | +3.62% | +24.54% | +0.00% |
| 2023-06-30 | +34.79% | +35.01% | +5.49% | +0.91% | +24.32% | +0.00% |
| 2023-03-31 | +34.79% | +39.27% | +4.99% | +0.53% | +20.56% | +0.00% |
| 2022-12-31 | +34.79% | +41.29% | +5.28% | +0.51% | +18.25% | +0.00% |
| 2022-10-18 | +34.79% | +47.36% | +4.86% | +0.54% | +12.59% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze PIRAMAL PHARMA with valuation, momentum and industry peers
- Compare PPLPHARMA with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare PPLPHARMA with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.